Lung cancer treatment response blood test study
Part of Cancer, Lungs & breathing clinical trials.
This study looks at a new blood test to predict how well standard-of-care chemotherapy plus immunotherapy works for people with advanced non-small cell lung cancer. It aims to personalize treatment by identifying patients who may benefit most, potentially improving outcomes and reducing unnecessary side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed stage IIIB or IV non-small cell lung cancer.
- You are about to start a standard combination of an immunotherapy drug (like pembrolizumab) and platinum-based chemotherapy.
- You are between 18 and 80 years old.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- You are willing to give extra blood samples at several time points during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study is testing whether certain white blood cells (called neutrophils) in your tumor can predict how well a combination of chemotherapy and immunotherapy works before surgery for lung cancer. If you qualify, you would receive this treatment and then have surgery, and researchers would track your response.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.